3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
4
Glioma
3
Multiple Myeloma
2
Lymphoma
2
Astrocytoma
2
Sarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lipodystrophy, Congenital Generalized
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hodgkin Disease
1
Gliosarcoma
1
Carcinoma
1
Advanced Fallopian Tube Carcinoma
1
Interventions
Cyclophosphamide
20
Etoposide
19
Temozolomide
16
Carboplatin
16
Filgrastim
15
Vincristine
11
Cisplatin
11
Radiotherapy
10
Thiotepa
9
Melphalan
8
Granulocyte Colony-Stimulating Factor
8
etoposide phosphate
7
Lomustine
7
Peripheral Blood Stem Cell Transplantation
6
Radiation
5
Methotrexate
5
Magnetic Resonance Spectroscopy
5
Topotecan
4
Mesna
4
Gemcitabine
4
Busulfan
4
sargramostim
3
gallium Ga 68 dotatate
3
Thalidomide
3
Stem Cell Transplantation
3
Irinotecan
3
Ifosfamide
3
Donepezil
3
Celecoxib
3
Automobiles
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Medulloblastoma
×
Tetanus Toxoid
×
Clear all
NCT03615404
2021-01-28
ATTAC-P
Duke University
Phase 1
Completed
11 enrolled
7 charts